Nemaura Medical Names Samantha Sanders as Global Head of Digital Programs

Nemaura Medical Inc. has welcomed a new member to its executive team.

The company recently appointed Samantha Sanders as the global head of Digital Programs.

“Samantha will lead the customer interface of Nemaura’s digital portfolio, from a product design, product placement, and customer service perspective. She takes a passionate approach to ensure that products are designed with the user in mind, developing and managing products that enhance everyday lives and we are looking forward to her contribution to ensure optimized access to our product portfolio for the end user,” commented Dr. Faz Chowdhury, Nemaura’s CEO.
 
Sanders has more than two decades of project development, management and customer service experience, delivering successful digital projects to market within the wellbeing, pharmaceutical and medical device sector, both locally and internationally. 
 
Prior to joining the Nemaura team, more recently Sanders has been instrumental in the commercialization of bringing medical and digital health products to market, working within the regulations and requirements of both CE and U.S. Food and Drug Administration (FDA) certification. She has previously supported the design and led the project development of digital applications for AbbVie Humira anti-TNF within the Asian healthcare market. Samantha has established a wealth of experience working across digital design, human-centered design and preparation of product pre/post launch strategies.
  
“Nemaura’s BEAT®diabetes program, and pipeline consumer metabolic health product are both very exciting alternatives to what’s currently available and I am delighted to play a leading role in enhancing the digital presence of these programs,” added Sanders.
 
Nemaura Medical Inc. is a medical technology company developing and commercializing non-invasive wearable diagnostic devices. The company is currently commercializing sugarBEAT and proBEAT. sugarBEAT, a CE mark approved Class IIb medical device, is a non-invasive and flexible continuous glucose monitor (CGM) providing actionable insights derived from real time glucose measurements and daily glucose trend data, which may help people with diabetes and pre-diabetes to better manage, reverse, and prevent the onset of diabetes. Nemaura has submitted a PMA (Premarket Approval Application) for sugarBEAT to the FDA. proBEAT combines non-invasive glucose data processed using artificial intelligence and a digital healthcare subscription service and has been launched in the United States as a general wellness product as part of its BEAT diabetes program.